Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Show more
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...
MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular...
With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after...
Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenuesFirst manufacturing services contract signed with Secretome...
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...
Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024Data from Phase 2a clinical trial evaluating Lomecel-BTM in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -7.30337078652 | 1.78 | 1.83 | 1.46 | 1048213 | 1.6691992 | CS |
4 | 0.59 | 55.6603773585 | 1.06 | 4.1 | 0.7707 | 21955519 | 2.60580762 | CS |
12 | -0.43 | -20.6730769231 | 2.08 | 4.24 | 0.7707 | 8418573 | 2.62584508 | CS |
26 | -11.55 | -87.5 | 13.2 | 13.623 | 0.7707 | 4448117 | 2.68563977 | CS |
52 | -31.45 | -95.0151057402 | 33.1 | 37.5 | 0.7707 | 2327377 | 3.69161045 | CS |
156 | -82.25 | -98.0333730632 | 83.9 | 450 | 0.7707 | 2353553 | 109.1678904 | CS |
260 | -98.35 | -98.35 | 100 | 450 | 0.7707 | 2152615 | 107.99191984 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.